Phase II Study of Z-206 in Patients with Active Crohn's Disease
Phase 2
- Conditions
- Active Crohn's disease
- Registration Number
- JPRN-jRCT2080221421
- Lead Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
CDAI score : 200 to less than 350
Patients in whom mucosal lesions are observed at the area between the terminal ileum and rectum
outpatient
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method